The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

89 articles for G Wu


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HTEBI
Bristol-Myers Squibb
Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors.EBI
Roche Innovation Center Shanghai
GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an ImprovedEBI
Genentech
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.EBI
Pharmaron-Beijing
Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.EBI
Xi'An Jiaotong University
Discovery of thieno[3,2-c]pyridin-4-amines as novel Bruton's tyrosine kinase (BTK) inhibitors.EBI
China Pharmaceutical University
Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels.EBI
Purdue Pharma
Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.EBI
Departments of Discovery Chemistry, Metabolic Diseases, Lead Evaluation, Computer-Assisted Drug Design, Discovery Toxicology, Exploratory Clinical and Translational Research, and Pharmaceutical Candi
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic properties.EBI
Bristol-Myers Squibb
Synthesis and SAR of 2,3,3a,4-tetrahydro-1H-pyrrolo[3,4-c]isoquinolin-5(9bH)-ones as 5-HT2C receptor agonists.EBI
Bristol-Myers Squibb Research and Development
3-Thiomorpholin-8-oxo-8H-acenaphtho [1,2-b] pyrrole-9-carbonitrile (S1) derivatives as pan-Bcl-2-inhibitors of Bcl-2, Bcl-xL and Mcl-1.EBI
Dalian University of Technology
Pentacyclic triterpenes. Part 3: Synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase.EBI
China Pharmaceutical University
Pentacyclic triterpenes. Part 1: the first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases.EBI
China Pharmaceutical University
Probing the difference between BH3 groove of Mcl-1 and Bcl-2 protein: Implications for dual inhibitors design.EBI
Dalian University of Technology
3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies.EBI
Dalian University of Technology
Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents.EBI
Bristol-Myers Squibb
Rational design and synthesis of highly potent anti-acetylcholinesterase activity huperzine A derivatives.EBI
The Chinese Academy of Sciences
 
Carboxyl-promoted enhancement of selectivity for the β3 adrenergic receptor. Negative charge of the sulfonic acid BMS-187413 introduces-β3 binding selectivityEBI
TBA
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.EBI
Bristol Myers Squibb
Design, synthesis and biological evaluation of N-salicyloyl tryptamine derivatives as multifunctional neuroprotectants for the treatment of ischemic stroke.EBI
University of South China
Discovery of potent HIV-1 NNRTIs by CuAAC click-chemistry-based miniaturized synthesis, rapid screening and structure optimization.EBI
Shandong University
Design, synthesis and antibacterial activity evaluation of ebselen derivatives in NDM-1 producing bacteria.EBI
Ocean University of China
pH regulators and their inhibitors in tumor microenvironment.EBI
University of South China
Synthesis and structure-activity optimization of 7-azaindoles containing aza-β-amino acids targeting the influenza PB2 subunit.EBI
Zhejiang University
Discovery of isonicotinamide derived beta-secretase inhibitors: in vivo reduction of beta-amyloid.EBI
TBA
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Exploration and Biological Evaluation of 1,3-Diamino-7EBI
Chinese Academy of Medical Sciences&Peking Union Medical College
Discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol- 6(2H)-one, a selective, orally active agonist of the 5-HT(2C) receptor.EBI
Pharmaceutical Research Institute
Recent progress toward developing axial chirality bioactive compounds.EBI
Shandong University
Discovery of conformationally constrained c-Abl inhibitors with potential neuroprotective effects against Parkinson's disease.EBI
Southern Medical University
Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines.EBI
Shanghai Institute of Materia Medica
Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection.EBI
China Innovation Center of Roche
Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.EBI
Zhejiang University
Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity.EBI
Merck
Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[EBI
China Pharmaceutical University
BMS-201620: a selective beta 3 agonist.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of BMS-986318, a Potent Nonbile Acid FXR Agonist for the Treatment of Nonalcoholic Steatohepatitis.EBI
Bristol-Myers Squibb
Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.EBI
Merck
BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptor.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir.EBI
Merck
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.EBI
Merck
Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.EBI
Merck
Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.EBI
Ocean University of China
Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.EBI
Roche Innovation Center Shanghai
Highly Potent and Selective Plasmin Inhibitors Based on the Sunflower Trypsin Inhibitor-1 Scaffold Attenuate Fibrinolysis in Plasma.EBI
The University of Queensland
Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.EBI
Shandong University
Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors.EBI
Genentech
Overview of Recent Strategic Advances in Medicinal Chemistry.EBI
Shandong University
Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries.EBI
Shandong University
Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT(2C) receptor agonists.EBI
Bristol-Myers Squibb Research and Development
Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library.EBI
Shandong University
Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.EBI
Shandong University
Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.EBI
Shandong University
Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-κB Inducing Kinase.EBI
Genentech
Aminoisoxazoles as Potent Inhibitors of Tryptophan 2,3-Dioxygenase 2 (TDO2).EBI
Genentech
Discovery of Thiophene[3,2-EBI
Shandong University
Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors.EBI
Shenyang Pharmaceutical University
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.EBI
Shandong University
Discovery of a Potent (4 R,5 S)-4-Fluoro-5-methylproline Sulfonamide Transient Receptor Potential Ankyrin 1 Antagonist and Its Methylene Phosphate Prodrug Guided by Molecular Modeling.EBI
Pharmaron-Beijing
Discovery of Potent Small-Molecule Inhibitors of Ubiquitin-Conjugating Enzyme UbcH5c fromα-Santonin Derivatives.EBI
Second Military Medical University
QUINOLINE COMPOUND AND USE THEREOFBDB
Shanghai Pharmaceuticals Holding Co.
Deuterated protease inhibitorsBDB
Kansas State University Research Foundation
ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETOBDB
Arena Pharmaceuticals
TREATMENT OF MYELOPROLIFERATIVE DISEASES AND DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAINBDB
Poseidon Innovation 1
COMPOUND USED AS KINASE INHIBITOR AND USE THEREOFBDB
Tyk Medicines
SARS-CoV-2 inhibitors for treating coronavirus infectionsBDB
Insilico Medicine Ip
Combination therapy for treatment of hematological diseasesBDB
Incyte
Substituted pyridines as inhibitors of histone deacetylaseBDB
Alkermes
Selective NR2B antagonistsBDB
Bristol-Myers Squibb
Bipyrazole derivatives as JAK inhibitorsBDB
Incyte
Autotaxin inhibitorsBDB
Cancer Research Technology
[5,6]—fused bicyclic antidiabetic compoundsBDB
Merck Sharp & Dohme
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonistsBDB
Bristol-Myers Squibb
Imidazopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseasesBDB
Bristol-Myers Squibb
Selective histone deactylase 6 inhibitorsBDB
H. Lee Moffitt Cancer Center and Research Institute
Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)BDB
University of California
Aniline derivatives, their preparation and their therapeutic applicationBDB
Fovea Pharmaceuticals
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivativesBDB
Reviva Pharmaceuticals
Selective NR2B antagonistsBDB
Bristol-Myers Squibb
Coumarin-thiazole and -oxadiazole derivatives: Synthesis, bioactivity and docking studies for aldose/aldehyde reductase inhibitors.BDB
Comsats Institute of Information Technology
Sulfamide sodium channel inhibitorsBDB
Amgen
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties.BDB
Purdue Pharma Discovery Research
Pharmacology and functions of metabotropic glutamate receptors.BDB
Emory University
Splicing factor SF3b as a target of the antitumor natural product pladienolide.BDB
Eisai